首页> 外文期刊>Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists >LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAIVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY
【24h】

LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAIVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY

机译:甘油肽治疗综合征:患者患者患者患者的前瞻性分析,响应于先前的奥葡萄酒治疗和幼稚素类似物在选择第3研究中的生长抑制素组合治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: This ELECT prospective analysis examined lanreotide depot/autogel for carcinoid syndrome (CS) symptom control in patients with neuroendocrine tumors (NETs) who were responsive to prior octreotide (prior octreotide group) compared with patients who were naive to prior somatostatin analogue treatment (de novo group).
机译:目的:这项选举前瞻性分析检测了对患有先前octreotide(先前octreotide Group)的神经内分泌肿瘤(蚊帐)患者的甘油肽综合征(CS)症状控制的血管肽综合症(CS)症状控制,与幼儿病毒素类似物治疗( de novo集团)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号